No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

AdaCore’s QGen Automated Code Generator Helps Develop New Artificial Lung Equipment to Treat Covid Patients in Only6 Months

Editor: What To Know

  • The easiest way to assure that is by using model-based systems engineering (MBSE) techniques to design and test the system, and then to generate the code for the target controller hardware directly from the model using an automated code generator, as provided by QGen.
  • QGen is an integral part of the process, delivering clean, readable code and ensuring accurate testing to ensure a high level of reliability and quality performance for the entire time the ECMO is in use.
  • It consists of a machine and a set of disposable devices, which together perform the circulation and oxygenation of the patient's blood outside his or her body.

Leading provider of software development and verification tools, AdaCore, has joined forces with the Eldorado Institute in Brazil and medical device manufacturer Braile Biomédica to help in the fight against COVID-19.

AdaCore’s code generation and model verification tool software suite, QGen, played an integral part in the development of Braile Biomédica’s new extracorporeal membrane oxygenation (ECMO) device to help COVID-19 sufferers experiencing blood oxygen deficits. Thanks to the technical expertise and dedication of all three organizations, what would have been a two-year development program has been completed in just six months.

AdaCore’s QGen is a qualifiable and tunable code generator for a safe subset of Simulink® and Stateflow® models. The Eldorado Institute had already used the software suite in a cardiac pacemaker pilot project. After using the pilot project to build up a mature understanding of how to use QGen in code generation and verification, they began applying QGen on other projects, including Braile Biomédica’s expedited ECMO device.

The Eldorado Institute (Eldorado) is a private research and technology organization (RTO) based in Brazil. It collaborates with technology companies around Brazil and in other countries to develop new products. Braile Biomédica initially partnered with Eldorado to develop hyperthermic intraperitoneal chemotherapy (HIPEC) equipment. Also known as “hot chemotherapy,” HIPEC is performed after tumors or lesions are removed from the abdominal area.

When the COVID-19 pandemic exploded in Brazil in March 2020, Braile Biomédica redeployed this technology into an ECMO device, designed to help patients battling the virus. The device supports patients with severe lung injuries, keeping the patient alive until the lung recovers and the disease regresses. It consists of a machine and a set of disposable devices, which together perform the circulation and oxygenation of the patient’s blood outside his or her body. QGen is an integral part of the process, delivering clean, readable code and ensuring accurate testing to ensure a high level of reliability and quality performance for the entire time the ECMO is in use.

The ECMO device had to be extremely reliable, regardless of the tight development timeframe. Treatments could last as long as thirty-forty days, during which time the ECMO is responsible for keeping the patient alive. High reliability in such a device is critical to patient survival. The easiest way to assure that is by using model-based systems engineering (MBSE) techniques to design and test the system, and then to generate the code for the target controller hardware directly from the model using an automated code generator, as provided by QGen.

AdaCore QGen Team Lead, JC Bernedo, says: “QGen is a trusted code generator, meaning that the source code it generates is guaranteed to be equivalent to the Simulink simulation environment and therefore directly usable without further manual review. This allows developers of critical systems to streamline their development, testing, and verification processes while providing additional safety guarantees to their customers. We are proud to have helped Braile Biomédica and The Eldorado Institute expedite the development of their life-saving ECMO device.”

Guilherme Fonseca, Manager of Research and Development at The Eldorado Institute adds: “When we were looking for a solution to our design testing and code generation requirements, we found that QGen best matched what we needed. It provided us with the best overall value, thanks to the easily readable generated code, and the guarantee of equivalence of behavior between the generated code and simulation. AdaCore showed us excellent partnership and support throughout the development process. Going forward, whenever we have an opportunity that demands development of high-risk, high-reliability software, we are going to use QGen to verify our model and generate high-reliability code.”

Full case study here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy